Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study

Stefan P Berger, Claudia Sommerer, Oliver Witzke, Helio Tedesco, Steve Chadban, Shamkant Mulgaonkar, Yasir Qazi, Johan W de Fijter, Federico Oppenheimer, Josep M Cruzado, Yoshihiko Watarai, Pablo Massari, Christophe Legendre, Franco Citterio, Mitchell Henry, Titte R Srinivas, Flavio Vincenti, Maria Pilar Hernandez Gutierrez, Ana Maria Marti, Peter Bernhardt, Julio Pascual, TRANSFORM investigators, Stefan P Berger, Claudia Sommerer, Oliver Witzke, Helio Tedesco, Steve Chadban, Shamkant Mulgaonkar, Yasir Qazi, Johan W de Fijter, Federico Oppenheimer, Josep M Cruzado, Yoshihiko Watarai, Pablo Massari, Christophe Legendre, Franco Citterio, Mitchell Henry, Titte R Srinivas, Flavio Vincenti, Maria Pilar Hernandez Gutierrez, Ana Maria Marti, Peter Bernhardt, Julio Pascual, TRANSFORM investigators

Abstract

TRANSFORM (TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen) was a 24-month, prospective, open-label trial in 2037 de novo renal transplant recipients randomized (1:1) within 24 hours of transplantation to receive everolimus (EVR) with reduced-exposure calcineurin inhibitor (EVR + rCNI) or mycophenolate with standard-exposure CNI. Consistent with previously reported 12-month findings, noninferiority of the EVR + rCNI regimen for the primary endpoint of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) <50 mL/min per 1.73 m2 was achieved at month 24 (47.9% vs 43.7%; difference = 4.2%; 95% confidence interval = -0.3, 8.7; P = .006). Mean eGFR was stable up to month 24 (52.6 vs 54.9 mL/min per 1.73 m2 ) in both arms. The incidence of de novo donor-specific antibodies (dnDSA) was lower in the EVR + rCNI arm (12.3% vs 17.6%) among on-treatment patients. Although discontinuation rates due to adverse events were higher with EVR + rCNI (27.2% vs 15.0%), rates of cytomegalovirus (2.8% vs 13.5%) and BK virus (5.8% vs 10.3%) infections were lower. Cytomegalovirus infection rates were significantly lower with EVR + rCNI even in the D+/R- high-risk group (P < .0001). In conclusion, the EVR + rCNI regimen offers comparable efficacy and graft function with low tBPAR and dnDSA rates and significantly lower incidence of viral infections relative to standard-of-care up to 24 months. Clinicaltrials.gov number: NCT01950819.

Keywords: clinical research/practice; immunosuppressant - mechanistic target of rapamycin (mTOR); immunosuppressant - mechanistic target of rapamycin: everolimus; immunosuppression/immune modulation; immunosuppressive regimens - minimization/withdrawal; kidney transplantation/nephrology; liver transplantation/hepatology.

© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

References

REFERENCES

    1. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant. 2011;11(4):693-697.
    1. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37(6):602-612.
    1. Sprangers B, Nair V, Launay-Vacher V, et al. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J. 2018;11(3):315-329.
    1. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis. 2005;18(4):342-345.
    1. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530-534.
    1. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 2003;76(3):597-602.
    1. Weikert BC, Blumberg EA. Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S76-S86.
    1. Erdbruegger U, Scheffner I, Mengel M, et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant. 2012;27(1):435-443.
    1. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66(1):329-337.
    1. Jouve T, Noble J, Rostaing L, et al. Tailoring tacrolimus therapy in kidney transplantation. Expert Rev Clin Pharmacol. 2018;11(6):581-588.
    1. Witzke O, Sommerer C, Arns W. Everolimus immunosuppression in kidney transplantation: what is the optimal strategy? Transplant Rev (Orlando). 2016;30(1):3-12.
    1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-2575.
    1. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876-1885.
    1. Tedesco Silva Jr H, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10(6):1401-1413.
    1. Cibrik D, Silva HT Jr, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation. 2013;95(7):933-942.
    1. Langer RM, Hene R, Vitko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25(5):592-602.
    1. Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant. 2017;17(5):1358-1369.
    1. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93(11):1075-1085.
    1. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11(11):2453-2462.
    1. Shihab F, Qazi Y, Mulgaonkar S, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant. 2017;17(9):2363-2371.
    1. Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol. 2017;12(8):1321-1336.
    1. Devresse A, Leruez-Ville M, Scemla A, et al. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. Transpl Infect Dis. 2018;20(2):e12846.
    1. Pascual J, Srinivas T, Chadban S, et al. TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access J Clin Trials. 2014;6:45-54.
    1. Kasiske BL, Israni AK, Snyder JJ, et al.; Patient Outcomes in Renal Transplantation I. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis. 2011;57(3):466-475.
    1. Srinivas TR, Oppenheimer F. Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival. Clin Transplant. 2015;29(7):644-653.
    1. Pascual J, Berger SP, Witzke O, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29(7):1979-1991.
    1. Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019; [Epub ahead of print].
    1. O'Leary JG, Samaniego M, Barrio MC, et al. The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. Transplantation. 2016;100(1):39-53.
    1. Perbos E, Juinier E, Guidicelli G, et al. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Clin Transplant. 2014;28(9):1054-1060.
    1. Budde K, Zeier M, Witzke O, et al. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrol Dial Transplant. 2017;32(6):1060-1070.
    1. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant. 2012;12(5):1192-1198.
    1. Pascual J, Diekmann F, Fernandez-Rivera C, et al. Recommendations for the use of everolimus in de novo kidney transplantation: false beliefs, myths and realities. Nefrologia. 2017;37(3):253-266.
    1. Davis S, Gralla J, Klem P, et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018;18(4):907-915.
    1. Wiebe C, Rush DN, Nevins TE, et al. Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol. 2017;28(11):3353-3362.
    1. Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant. 2013;27(2):217-226.
    1. Cristelli MP, Esmeraldo RM, Pinto CM, et al. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R−) kidney transplant recipients. Transpl Infect Dis. 2018;20(4):e12907.
    1. Suwelack B, Malyar V, Koch M, et al. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando). 2012;26(3):201-211.
    1. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5(3):582-594.
    1. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488-496.
    1. van Doesum WB, Gard L, Bemelman FJ, et al. Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine-, mycophenolate sodium-, or everolimus-based low-dose immunosuppressive therapy. Transpl Infect Dis. 2017;19(3):e12687.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi